-
1
-
-
84876092424
-
Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma
-
Kirstein MM, Boukouris AE, Pothiraju D, Buitrago-Molina LE, Marhenke S, Schutt J, Orlik J, Kuhnel F, Hegermann J, Manns MP and Vogel A. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma. Liver Int. 2013; 33: 780-793.
-
(2013)
Liver Int.
, vol.33
, pp. 780-793
-
-
Kirstein, M.M.1
Boukouris, A.E.2
Pothiraju, D.3
Buitrago-Molina, L.E.4
Marhenke, S.5
Schutt, J.6
Orlik, J.7
Kuhnel, F.8
Hegermann, J.9
Manns, M.P.10
Vogel, A.11
-
2
-
-
84857358680
-
Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?
-
Asghar U and Meyer T. Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol. 2012; 56: 686-695.
-
(2012)
J Hepatol.
, vol.56
, pp. 686-695
-
-
Asghar, U.1
Meyer, T.2
-
3
-
-
34047095297
-
The two TORCs and Akt
-
Bhaskar PT and Hay N. The two TORCs and Akt. Dev Cell. 2007; 12: 487-502.
-
(2007)
Dev Cell.
, vol.12
, pp. 487-502
-
-
Bhaskar, P.T.1
Hay, N.2
-
4
-
-
84871491627
-
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance
-
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Basecke J, Mijatovic S, Maksimovic-Ivanic D, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget. 2012; 3: 1068-1111.
-
(2012)
Oncotarget.
, vol.3
, pp. 1068-1111
-
-
McCubrey, J.A.1
Steelman, L.S.2
Chappell, W.H.3
Abrams, S.L.4
Franklin, R.A.5
Montalto, G.6
Cervello, M.7
Libra, M.8
Candido, S.9
Malaponte, G.10
Mazzarino, M.C.11
Fagone, P.12
Nicoletti, F.13
Basecke, J.14
Mijatovic, S.15
Maksimovic-Ivanic, D.16
-
5
-
-
84864561983
-
Molecular mechanisms of sorafenib action in liver cancer cells
-
Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, McCubrey JA and Montalto G. Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle. 2012; 11: 2843-2855.
-
(2012)
Cell Cycle.
, vol.11
, pp. 2843-2855
-
-
Cervello, M.1
Bachvarov, D.2
Lampiasi, N.3
Cusimano, A.4
Azzolina, A.5
McCubrey, J.A.6
Montalto, G.7
-
6
-
-
84864558037
-
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon
-
Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A and Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget. 2012; 3: 236-260.
-
(2012)
Oncotarget.
, vol.3
, pp. 236-260
-
-
Cervello, M.1
McCubrey, J.A.2
Cusimano, A.3
Lampiasi, N.4
Azzolina, A.5
Montalto, G.6
-
7
-
-
84868610892
-
Glyceraldehyde-3-phosphate dehydrogenase: a promising target for molecular therapy in hepatocellular carcinoma
-
Ganapathy-Kanniappan S, Kunjithapatham R and Geschwind JF. Glyceraldehyde-3-phosphate dehydrogenase: a promising target for molecular therapy in hepatocellular carcinoma. Oncotarget. 2012; 3: 940-953.
-
(2012)
Oncotarget.
, vol.3
, pp. 940-953
-
-
Ganapathy-Kanniappan, S.1
Kunjithapatham, R.2
Geschwind, J.F.3
-
8
-
-
67749122122
-
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
-
Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9: 550-562.
-
(2009)
Nat Rev Cancer.
, vol.9
, pp. 550-562
-
-
Engelman, J.A.1
-
9
-
-
84856051905
-
Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells
-
Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Steelman LS and McCubrey JA. Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. Oncotarget. 2011; 2: 610-626.
-
(2011)
Oncotarget.
, vol.2
, pp. 610-626
-
-
Taylor, J.R.1
Lehmann, B.D.2
Chappell, W.H.3
Abrams, S.L.4
Steelman, L.S.5
McCubrey, J.A.6
-
11
-
-
39049151617
-
Deregulation of the Akt pathway in human cancer
-
Tokunaga E, Oki E, Egashira A, Sadanaga N, Morita M, Kakeji Y and Maehara Y. Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets. 2008; 8: 27-36.
-
(2008)
Curr Cancer Drug Targets.
, vol.8
, pp. 27-36
-
-
Tokunaga, E.1
Oki, E.2
Egashira, A.3
Sadanaga, N.4
Morita, M.5
Kakeji, Y.6
Maehara, Y.7
-
12
-
-
43749120732
-
The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications
-
Carnero A, Blanco-Aparicio C, Renner O, Link W and Leal JF. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 2008; 8: 187-198.
-
(2008)
Curr Cancer Drug Targets.
, vol.8
, pp. 187-198
-
-
Carnero, A.1
Blanco-Aparicio, C.2
Renner, O.3
Link, W.4
Leal, J.F.5
-
13
-
-
84879771957
-
Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: Implications for the treatment of human liver cancer
-
Wang C, Cigliano A, Delogu S, Armbruster J, Dombrowski F, Evert M, Chen X and Calvisi DF. Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: Implications for the treatment of human liver cancer. Cell Cycle. 2013; 12: 1999-2010.
-
(2013)
Cell Cycle.
, vol.12
, pp. 1999-2010
-
-
Wang, C.1
Cigliano, A.2
Delogu, S.3
Armbruster, J.4
Dombrowski, F.5
Evert, M.6
Chen, X.7
Calvisi, D.F.8
-
14
-
-
0344407448
-
Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma
-
Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, Changchien CS, Lee CM and Tai MH. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer. 2003; 97: 1929-1940.
-
(2003)
Cancer.
, vol.97
, pp. 1929-1940
-
-
Hu, T.H.1
Huang, C.C.2
Lin, P.R.3
Chang, H.W.4
Ger, L.P.5
Lin, Y.W.6
Changchien, C.S.7
Lee, C.M.8
Tai, M.H.9
-
15
-
-
34648834791
-
Expression of PTEN, PPM1A and P-Smad2 in hepatocellular carcinomas and adjacent liver tissues
-
Wu SK, Wang BJ, Yang Y, Feng XH, Zhao XP and Yang DL. Expression of PTEN, PPM1A and P-Smad2 in hepatocellular carcinomas and adjacent liver tissues. WJG. 2007; 13: 4554-4559.
-
(2007)
WJG.
, vol.13
, pp. 4554-4559
-
-
Wu, S.K.1
Wang, B.J.2
Yang, Y.3
Feng, X.H.4
Zhao, X.P.5
Yang, D.L.6
-
16
-
-
84869194238
-
Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
-
Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B and Jucker M. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer. 2012; 11: 85.
-
(2012)
Mol Cancer.
, vol.11
, pp. 85
-
-
Grabinski, N.1
Ewald, F.2
Hofmann, B.T.3
Staufer, K.4
Schumacher, U.5
Nashan, B.6
Jucker, M.7
-
17
-
-
1542328927
-
Structure, regulation and function of PKB/AKT--a major therapeutic target
-
Hanada M, Feng J and Hemmings BA. Structure, regulation and function of PKB/AKT--a major therapeutic target. Biochim Biophys Acta. 2004; 1697: 3-16.
-
(2004)
Biochim Biophys Acta.
, vol.1697
, pp. 3-16
-
-
Hanada, M.1
Feng, J.2
Hemmings, B.A.3
-
18
-
-
84862933157
-
MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis
-
Cheng Y, Zhang Y, Zhang L, Ren X, Huber-Keener KJ, Liu X, Zhou L, Liao J, Keihack H, Yan L, Rubin E and Yang JM. MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther. 2012; 11: 154-164.
-
(2012)
Mol Cancer Ther.
, vol.11
, pp. 154-164
-
-
Cheng, Y.1
Zhang, Y.2
Zhang, L.3
Ren, X.4
Huber-Keener, K.J.5
Liu, X.6
Zhou, L.7
Liao, J.8
Keihack, H.9
Yan, L.10
Rubin, E.11
Yang, J.M.12
-
19
-
-
84869086211
-
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia
-
Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F, Evangelisti C, Cani A, Tazzari PL, Melchionda F, Pagliaro P, Pession A, McCubrey JA, Capitani S and Martelli AM. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia. 2012; 26: 2336-2342.
-
(2012)
Leukemia.
, vol.26
, pp. 2336-2342
-
-
Simioni, C.1
Neri, L.M.2
Tabellini, G.3
Ricci, F.4
Bressanin, D.5
Chiarini, F.6
Evangelisti, C.7
Cani, A.8
Tazzari, P.L.9
Melchionda, F.10
Pagliaro, P.11
Pession, A.12
McCubrey, J.A.13
Capitani, S.14
Martelli, A.M.15
-
20
-
-
79961173138
-
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
-
Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging. 2011; 3: 192-222.
-
(2011)
Aging.
, vol.3
, pp. 192-222
-
-
Steelman, L.S.1
Chappell, W.H.2
Abrams, S.L.3
Kempf, R.C.4
Long, J.5
Laidler, P.6
Mijatovic, S.7
Maksimovic-Ivanic, D.8
Stivala, F.9
Mazzarino, M.C.10
Donia, M.11
Fagone, P.12
Malaponte, G.13
Nicoletti, F.14
Libra, M.15
Milella, M.16
-
21
-
-
53749104349
-
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents
-
Degtyarev M, De Maziere A, Orr C, Lin J, Lee BB, Tien JY, Prior WW, van Dijk S, Wu H, Gray DC, Davis DP, Stern HM, Murray LJ, Hoeflich KP, Klumperman J, Friedman LS, et al. Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol. 2008; 183: 101-116.
-
(2008)
J Cell Biol.
, vol.183
, pp. 101-116
-
-
Degtyarev, M.1
De Maziere, A.2
Orr, C.3
Lin, J.4
Lee, B.B.5
Tien, J.Y.6
Prior, W.W.7
van Dijk, S.8
Wu, H.9
Gray, D.C.10
Davis, D.P.11
Stern, H.M.12
Murray, L.J.13
Hoeflich, K.P.14
Klumperman, J.15
Friedman, L.S.16
-
22
-
-
84857698541
-
Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma
-
Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, Hiramatsu N, Fujita N, Yoshimori T and Hayashi N. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer. 2012; 131: 548-557.
-
(2012)
Int J Cancer.
, vol.131
, pp. 548-557
-
-
Shimizu, S.1
Takehara, T.2
Hikita, H.3
Kodama, T.4
Tsunematsu, H.5
Miyagi, T.6
Hosui, A.7
Ishida, H.8
Tatsumi, T.9
Kanto, T.10
Hiramatsu, N.11
Fujita, N.12
Yoshimori, T.13
Hayashi, N.14
-
24
-
-
80052415530
-
Coordinated epigenetic regulation of autophagy and apoptosis
-
Boehrer S, Lainey E and Kroemer G. Coordinated epigenetic regulation of autophagy and apoptosis. Cell Cycle. 2011; 10: 2832-2833.
-
(2011)
Cell Cycle.
, vol.10
, pp. 2832-2833
-
-
Boehrer, S.1
Lainey, E.2
Kroemer, G.3
-
25
-
-
80052906831
-
Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia
-
Boehrer S, Galluzzi L, Lainey E, Bouteloup C, Tailler M, Harper F, Pierron G, Ades L, Thepot S, Sebert M, Gardin C, de Botton S, Fenaux P and Kroemer G. Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia. Cell Cycle. 2011; 10: 3168-3175.
-
(2011)
Cell Cycle.
, vol.10
, pp. 3168-3175
-
-
Boehrer, S.1
Galluzzi, L.2
Lainey, E.3
Bouteloup, C.4
Tailler, M.5
Harper, F.6
Pierron, G.7
Ades, L.8
Thepot, S.9
Sebert, M.10
Gardin, C.11
de Botton, S.12
Fenaux, P.13
Kroemer, G.14
-
26
-
-
84859562694
-
Targeting autophagy addiction in cancer
-
Mancias JD and Kimmelman AC. Targeting autophagy addiction in cancer. Oncotarget. 2011; 2: 1302-1306.
-
(2011)
Oncotarget.
, vol.2
, pp. 1302-1306
-
-
Mancias, J.D.1
Kimmelman, A.C.2
-
27
-
-
84867328500
-
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies
-
Ricciardi MR, Scerpa MC, Bergamo P, Ciuffreda L, Petrucci MT, Chiaretti S, Tavolaro S, Mascolo MG, Abrams SL, Steelman LS, Tsao T, Marchetti A, Konopleva M, Del Bufalo D, Cognetti F, Foa R, et al. Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. J Mol Med. 2012; 90: 1133-1144.
-
(2012)
J Mol Med.
, vol.90
, pp. 1133-1144
-
-
Ricciardi, M.R.1
Scerpa, M.C.2
Bergamo, P.3
Ciuffreda, L.4
Petrucci, M.T.5
Chiaretti, S.6
Tavolaro, S.7
Mascolo, M.G.8
Abrams, S.L.9
Steelman, L.S.10
Tsao, T.11
Marchetti, A.12
Konopleva, M.13
Del Bufalo, D.14
Cognetti, F.15
Foa, R.16
-
28
-
-
80053307869
-
Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers
-
Corcoran RB, Settleman J and Engelman JA. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget. 2011; 2: 336-346.
-
(2011)
Oncotarget.
, vol.2
, pp. 336-346
-
-
Corcoran, R.B.1
Settleman, J.2
Engelman, J.A.3
-
29
-
-
79959712087
-
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health
-
Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Basecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2011; 2: 135-164.
-
(2011)
Oncotarget.
, vol.2
, pp. 135-164
-
-
Chappell, W.H.1
Steelman, L.S.2
Long, J.M.3
Kempf, R.C.4
Abrams, S.L.5
Franklin, R.A.6
Basecke, J.7
Stivala, F.8
Donia, M.9
Fagone, P.10
Malaponte, G.11
Mazzarino, M.C.12
Nicoletti, F.13
Libra, M.14
Maksimovic-Ivanic, D.15
Mijatovic, S.16
-
30
-
-
84868628069
-
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response
-
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget. 2012; 3: 954-987.
-
(2012)
Oncotarget.
, vol.3
, pp. 954-987
-
-
McCubrey, J.A.1
Steelman, L.S.2
Chappell, W.H.3
Abrams, S.L.4
Montalto, G.5
Cervello, M.6
Nicoletti, F.7
Fagone, P.8
Malaponte, G.9
Mazzarino, M.C.10
Candido, S.11
Libra, M.12
Basecke, J.13
Mijatovic, S.14
Maksimovic-Ivanic, D.15
Milella, M.16
-
31
-
-
84874737273
-
Advances in targeting signal transduction pathways
-
McCubrey JA, Steelman LS, Chappell WH, Sun L, Davis NM, Abrams SL, Franklin RA, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Libra M, Candido S, Ligresti G, Malaponte G, Mazzarino MC, et al. Advances in targeting signal transduction pathways. Oncotarget. 2012; 3: 1505-1521.
-
(2012)
Oncotarget.
, vol.3
, pp. 1505-1521
-
-
McCubrey, J.A.1
Steelman, L.S.2
Chappell, W.H.3
Sun, L.4
Davis, N.M.5
Abrams, S.L.6
Franklin, R.A.7
Cocco, L.8
Evangelisti, C.9
Chiarini, F.10
Martelli, A.M.11
Libra, M.12
Candido, S.13
Ligresti, G.14
Malaponte, G.15
Mazzarino, M.C.16
-
32
-
-
84868626073
-
The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes
-
Singhal R and Kandel ES. The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes. Oncotarget. 2012; 3: 700-708.
-
(2012)
Oncotarget.
, vol.3
, pp. 700-708
-
-
Singhal, R.1
Kandel, E.S.2
-
33
-
-
65949125078
-
Beyond apoptosis of JNK1 in liver cancer
-
Chen F and Castranova V. Beyond apoptosis of JNK1 in liver cancer. Cell Cycle. 2009; 8: 1145-1147.
-
(2009)
Cell Cycle.
, vol.8
, pp. 1145-1147
-
-
Chen, F.1
Castranova, V.2
-
34
-
-
77749261166
-
Tyrosine kinase inhibitors to treat liver cancer
-
Huynh H. Tyrosine kinase inhibitors to treat liver cancer. Expert Opin Emerg Drugs. 2010; 15: 13-26.
-
(2010)
Expert Opin Emerg Drugs.
, vol.15
, pp. 13-26
-
-
Huynh, H.1
-
35
-
-
34848881905
-
Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma
-
Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM and Thorgeirsson SS. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest. 2007; 117: 2713-2722.
-
(2007)
J Clin Invest.
, vol.117
, pp. 2713-2722
-
-
Calvisi, D.F.1
Ladu, S.2
Gorden, A.3
Farina, M.4
Lee, J.S.5
Conner, E.A.6
Schroeder, I.7
Factor, V.M.8
Thorgeirsson, S.S.9
-
36
-
-
0037054934
-
Impact of PTEN expression on the outcome of hepatitis C virus-positive cirrhotic hepatocellular carcinoma patients: possible relationship with COX II and inducible nitric oxide synthase
-
Rahman MA, Kyriazanos ID, Ono T, Yamanoi A, Kohno H, Tsuchiya M and Nagasue N. Impact of PTEN expression on the outcome of hepatitis C virus-positive cirrhotic hepatocellular carcinoma patients: possible relationship with COX II and inducible nitric oxide synthase. Int J Cancer. 2002; 100: 152-157.
-
(2002)
Int J Cancer.
, vol.100
, pp. 152-157
-
-
Rahman, M.A.1
Kyriazanos, I.D.2
Ono, T.3
Yamanoi, A.4
Kohno, H.5
Tsuchiya, M.6
Nagasue, N.7
-
37
-
-
84984541581
-
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells
-
Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH, Chen PJ and Cheng AL. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther. 2011; 337: 155-161.
-
(2011)
J Pharmacol Exp Ther.
, vol.337
, pp. 155-161
-
-
Chen, K.F.1
Chen, H.L.2
Tai, W.T.3
Feng, W.C.4
Hsu, C.H.5
Chen, P.J.6
Cheng, A.L.7
-
38
-
-
84880070521
-
Nilotinib Induces Autophagy in Hepatocellular Carcinoma through AMPK Activation
-
Yu HC, Lin CS, Tai WT, Liu CY, Shiau CW and Chen KF. Nilotinib Induces Autophagy in Hepatocellular Carcinoma through AMPK Activation. J Biol Chem. 2013; 288: 18249-18259.
-
(2013)
J Biol Chem.
, vol.288
, pp. 18249-18259
-
-
Yu, H.C.1
Lin, C.S.2
Tai, W.T.3
Liu, C.Y.4
Shiau, C.W.5
Chen, K.F.6
-
40
-
-
0035911162
-
Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells
-
Mizushima N, Yamamoto A, Hatano M, Kobayashi Y, Kabeya Y, Suzuki K, Tokuhisa T, Ohsumi Y and Yoshimori T. Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells. J Cell Biol. 2001; 152: 657-668.
-
(2001)
J Cell Biol.
, vol.152
, pp. 657-668
-
-
Mizushima, N.1
Yamamoto, A.2
Hatano, M.3
Kobayashi, Y.4
Kabeya, Y.5
Suzuki, K.6
Tokuhisa, T.7
Ohsumi, Y.8
Yoshimori, T.9
-
41
-
-
0034329418
-
LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing
-
Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y and Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000; 19: 5720-5728.
-
(2000)
EMBO J.
, vol.19
, pp. 5720-5728
-
-
Kabeya, Y.1
Mizushima, N.2
Ueno, T.3
Yamamoto, A.4
Kirisako, T.5
Noda, T.6
Kominami, E.7
Ohsumi, Y.8
Yoshimori, T.9
-
42
-
-
79952229430
-
Pancreatic cancers require autophagy for tumor growth
-
Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H, Bause A, Li Y, Stommel JM, Dell'antonio G, Mautner J, Tonon G, Haigis M, Shirihai OS, Doglioni C, Bardeesy N, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev. 2011; 25: 717-729.
-
(2011)
Genes Dev.
, vol.25
, pp. 717-729
-
-
Yang, S.1
Wang, X.2
Contino, G.3
Liesa, M.4
Sahin, E.5
Ying, H.6
Bause, A.7
Li, Y.8
Stommel, J.M.9
Dell'antonio, G.10
Mautner, J.11
Tonon, G.12
Haigis, M.13
Shirihai, O.S.14
Doglioni, C.15
Bardeesy, N.16
-
43
-
-
84871940714
-
Chloroquine in cancer therapy: a double-edged sword of autophagy
-
Kimura T, Takabatake Y, Takahashi A and Isaka Y. Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res. 2013; 73: 3-7.
-
(2013)
Cancer Res.
, vol.73
, pp. 3-7
-
-
Kimura, T.1
Takabatake, Y.2
Takahashi, A.3
Isaka, Y.4
-
44
-
-
84055190665
-
Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop
-
Valenti F, Fausti F, Biagioni F, Shay T, Fontemaggi G, Domany E, Yaffe MB, Strano S, Blandino G and Di Agostino S. Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle. 2011; 10: 4330-4340.
-
(2011)
Cell Cycle.
, vol.10
, pp. 4330-4340
-
-
Valenti, F.1
Fausti, F.2
Biagioni, F.3
Shay, T.4
Fontemaggi, G.5
Domany, E.6
Yaffe, M.B.7
Strano, S.8
Blandino, G.9
Di Agostino, S.10
-
45
-
-
84874728272
-
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia
-
Chiarini F, Lonetti A, Teti G, Orsini E, Bressanin D, Cappellini A, Ricci F, Tazzari PL, Ognibene A, Falconi M, Pagliaro P, Iacobucci I, Martinelli G, Amadori S, McCubrey JA and Martelli AM. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. Oncotarget. 2012; 3: 1615-1628.
-
(2012)
Oncotarget.
, vol.3
, pp. 1615-1628
-
-
Chiarini, F.1
Lonetti, A.2
Teti, G.3
Orsini, E.4
Bressanin, D.5
Cappellini, A.6
Ricci, F.7
Tazzari, P.L.8
Ognibene, A.9
Falconi, M.10
Pagliaro, P.11
Iacobucci, I.12
Martinelli, G.13
Amadori, S.14
McCubrey, J.A.15
Martelli, A.M.16
-
46
-
-
84868614691
-
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels
-
Bressanin D, Evangelisti C, Ricci F, Tabellini G, Chiarini F, Tazzari PL, Melchionda F, Buontempo F, Pagliaro P, Pession A, McCubrey JA and Martelli AM. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. Oncotarget. 2012; 3: 811-823.
-
(2012)
Oncotarget.
, vol.3
, pp. 811-823
-
-
Bressanin, D.1
Evangelisti, C.2
Ricci, F.3
Tabellini, G.4
Chiarini, F.5
Tazzari, P.L.6
Melchionda, F.7
Buontempo, F.8
Pagliaro, P.9
Pession, A.10
McCubrey, J.A.11
Martelli, A.M.12
-
47
-
-
80052398902
-
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells
-
Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, Cocco L, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA and McCubrey JA. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle. 2011; 10: 3003-3015.
-
(2011)
Cell Cycle.
, vol.10
, pp. 3003-3015
-
-
Steelman, L.S.1
Navolanic, P.2
Chappell, W.H.3
Abrams, S.L.4
Wong, E.W.5
Martelli, A.M.6
Cocco, L.7
Stivala, F.8
Libra, M.9
Nicoletti, F.10
Drobot, L.B.11
Franklin, R.A.12
McCubrey, J.A.13
-
48
-
-
84863808495
-
Activity of the selective IkappaB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a
-
Buontempo F, Chiarini F, Bressanin D, Tabellini G, Melchionda F, Pession A, Fini M, Neri LM, McCubrey JA and Martelli AM. Activity of the selective IkappaB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a. Cell Cycle. 2012; 11: 2467-2475.
-
(2012)
Cell Cycle.
, vol.11
, pp. 2467-2475
-
-
Buontempo, F.1
Chiarini, F.2
Bressanin, D.3
Tabellini, G.4
Melchionda, F.5
Pession, A.6
Fini, M.7
Neri, L.M.8
McCubrey, J.A.9
Martelli, A.M.10
-
49
-
-
84870866737
-
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine
-
Chappell WH, Abrams SL, Franklin RA, LaHair MM, Montalto G, Cervello M, Martelli AM, Nicoletti F, Candido S, Libra M, Polesel J, Talamini R, Milella M, Tafuri A, Steelman LS and McCubrey JA. Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. Cell Cycle. 2012; 11: 4447-4461.
-
(2012)
Cell Cycle.
, vol.11
, pp. 4447-4461
-
-
Chappell, W.H.1
Abrams, S.L.2
Franklin, R.A.3
LaHair, M.M.4
Montalto, G.5
Cervello, M.6
Martelli, A.M.7
Nicoletti, F.8
Candido, S.9
Libra, M.10
Polesel, J.11
Talamini, R.12
Milella, M.13
Tafuri, A.14
Steelman, L.S.15
McCubrey, J.A.16
|